Effectiveness and Safety of Fast Enteral Feeding in Preterm Infants Between 1000 and 2000 Grams of Birth Weight

NCT ID: NCT02998489

Last Updated: 2018-03-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-01

Study Completion Date

2016-09-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized controlled trial with infants less than 34 weeks and between 1000 and 2000 grams at birth, that seeks to establish the safety and effectiveness of fast enteral advancement (milk 30-40 cc/kg/d) compared with traditional advancement (milk 20 cc/kg/d)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Progression of enteral feeding in preterm infants is still controversial. The neonatologist needs to provide adequate caloric intake avoiding the risk of food intolerance and necrotizing enterocolitis.

Objective: To establish the safety and effectiveness of fast enteral advancement compared with traditional advancement.

Design: A randomized controlled clinical trial with infants less than 34 weeks and between 1000 and 2000 grams at birth conducted at Hospital Universitario San Ignacio in Bogotá, Colombia.

Methods: 30 cc versus 20 cc / kg / day advancing in infants between 1000 and 1499g and 40cc versus 20 cc / kg / day advancing in infants between 1500 and 1999g.

Outcomes: days to reach full enteral nutrition, days of parenteral nutrition (PN) and/or intravenous fluids (IVF), days to regain birth weight, episodes of food intolerance, anthropometric measurements and weight gain at 40 weeks; rate of late onset sepsis, hypoglycemia, hyperbilirubinemia, necrotizing enterocolitis (NEC) and mortality. Data will be analyzed with Student t test or Mann-Whitney U-test and Pearson Chi-square or Fisher test. Multiple linear regression will be performed.

Ethics: This Protocol was approved by the Ethics and Research Committee of Pontificia Universidad Javeriana and San Ignacio Hospital. Informed consent will be requested to parents.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Feeding Behavior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fast milk advancement

30-40 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction

Group Type EXPERIMENTAL

Fast milk advancement

Intervention Type OTHER

30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved

Traditional milk advancement

20 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction

Group Type ACTIVE_COMPARATOR

Traditional milk advancement

Intervention Type OTHER

20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fast milk advancement

30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved

Intervention Type OTHER

Traditional milk advancement

20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Milk Milk

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants less than 34 weeks of gestational age.
* Weight at birth between 1000 and 2000 grams.
* Infants hospitalized in the newborn unit at Hospital Universitario San Ignacio in Bogotá, Colombia.

Exclusion Criteria

* Perinatal Asphyxia
* Intrauterine Growth Restriction
* Diagnosis of Congenital Hearth Disease
* Severe Hypoxemia
* Major Congenital Malformations
* Metabolic Disease
* Intolerance to initiate oral feeding at the eligibility
* Patent Ductus with hemodynamic instability
* Early Onset Sepsis with hemodynamic instability
* Refusal of parents to participate in the study
Maximum Eligible Age

72 Hours

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Universitario San Ignacio

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Adriana Montealegre, Dr.

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario San Ignacio

References

Explore related publications, articles, or registry entries linked to this study.

Morgan J, Young L, McGuire W. Slow advancement of enteral feed volumes to prevent necrotising enterocolitis in very low birth weight infants. Cochrane Database Syst Rev. 2015 Oct 15;(10):CD001241. doi: 10.1002/14651858.CD001241.pub6.

Reference Type RESULT
PMID: 26469124 (View on PubMed)

Moore TA, Wilson ME. Feeding intolerance: a concept analysis. Adv Neonatal Care. 2011 Jun;11(3):149-54. doi: 10.1097/ANC.0b013e31821ba28e.

Reference Type RESULT
PMID: 21730906 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014/25

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.